Biosimilars reimbursement update: Ontario adds Inclunox™ to its list of reimbursed drugs

As of May 31, 2021, ^PrInclunox™ and ^PrInclunox™ HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency)) will be eligible for reimbursement under the Ontario Drug Benefit program. This includes the six indications covered by the reference biologic medicine (Sanofi’s ^PrLovenox^® and ^PrLovenox^® HP).

Sandoz Canada congratulates Ontario on this addition, which may expand the use of biosimilars in the province, provide patients with greater access to biologic treatments and generate cost savings that can be redirected to new therapies and patient care.

Click here to read the news.

For more information on Sandoz Canada biosimilars, click here. For evidence-based information on biosimilars in Canada, visit The Biosimilars Generation website.

^{*Inclunox is a trademark owned or used under license by Sandoz Canada Inc. Lovenox is a registered trademark owned or used under license by Sanofi Aventis Canada.}